Dar Al Dawa Development and Investment Company PSC

Dar Al Dawa has a debt-to-equity ratio of 0.89, indicating a moderate reliance on debt financing, and a current ratio of 1.22, suggesting limited short-term liquidity cushion. The company's negative operating cash flow of -1.94 million JOD contrasts with a free cash flow of 0.53 million JOD, which is supported by capital expenditures of -0.81 million JOD. The return on equity of 1.02% and return on assets of 0.42% are below the typical thresholds for pharmaceutical firms, which often require higher returns to justify R&D investments.

The company's profitability metrics, including a gross margin of 43.0% and an operating margin of 8.0%, are in line with the industry's median gross margin of 45.0% but below the median operating margin of 10.0%. This suggests that while Dar Al Dawa is managing production costs effectively, it is underperforming in converting those efficiencies into operating profits.

Geographically and segment-wise, the company's revenue is concentrated in a single segment, with no disclosed geographic breakdown. This lack of diversification increases exposure to regional economic or regulatory shifts, which is a concern for long-term stability.

The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The absence of a clear growth strategy or expansion plans in the latest filings raises questions about its ability to scale operations or enter new markets.

The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is rated as low, with no evidence of recent share issuance or plans for future dilution. However, the negative operating cash flow and reliance on debt financing could pressure the company to raise additional capital in the future.

Recent filings and transcripts do not provide specific details on strategic initiatives or operational changes. The company's financial disclosures are limited to standard reporting, with no mention of new product launches, partnerships, or regulatory approvals that could drive future performance.

Net income surged 82.6% year-over-year to JOD 6.5 million, demonstrating strong recent profitability growth.

Free cash flow increased 52.4% to JOD 5.8 million, indicating improved operational cash generation capabilities.

Operating margin of 8.0% exceeds the pharmaceutical cohort median of 5.4%, suggesting superior cost efficiency.

Net income grew at a 34.7% compound annual rate over four years, showing consistent long-term earnings expansion.

Revenue reached JOD 81.6 million in the latest period, maintaining stable top-line performance despite market fluctuations.

Debt-to-equity ratio of 0.89 places the company in the bottom quartile of its pharmaceutical peer cohort.

The company faces high credit risk, which could impair its ability to secure favorable financing terms in the future.

Cash conversion metric of -4.08 ranks in the bottom quartile, signaling potential issues with working capital management.

Revenue JOD 60.4M, +16,6% YoY; Operating income +41,3% YoY.

• ▍Revenue JOD 60.4M, +16,6% YoY
• ▍Operating income +41,3% YoY
• ▍Net income +88,8% YoY
• ▍Free cash flow +24,6% YoY
• ▍Net margin 3.3%